Home›Stock Screener›Supriya Lifescience›Financial Statements

Supriya Lifescience Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2026, Supriya Lifescience (SUPRIYA) reported revenue ₹828 Cr, net profit ₹213 Cr and EPS ₹25.98, with a net profit margin of 25.7% and ROE of 17.8%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Supriya Lifescience stock price NSE.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 25.72% 2026 data
EBITDA Margin 35.51% 2026 data
Operating Margin 35.00% 2026 data
Return on Assets 15.70% 2026 data
Return on Equity 17.78% 2026 data

Balance Sheet Ratios

Current Ratio 14.00 2026 data
Equity Ratio 88.28% 2026 data
Asset Turnover 0.61 2026 data

SUPRIYA Revenue, Net Profit & EBITDA — Year-on-Year Growth

SUPRIYA YoY (March 2025 vs March 2026) — revenue +17.3%, net profit +13.3%, EBITDA +8.5%, expenses +22.5%. Analyse SUPRIYA promoter holding to track promoter, FII and institutional holdings.

Revenue Growth
+17.3%
Year-over-Year
Net Profit Growth
+13.3%
Year-over-Year
EBITDA Growth
+8.5%
Year-over-Year
Expense Growth
+22.5%
Year-over-Year
Assets Growth
+22.0%
Year-over-Year
Equity Growth
+20.2%
Year-over-Year
Operating Cash Flow Growth
+46.0%
Year-over-Year
Investing Cash Flow Growth
+12.6%
Year-over-Year
Financing Cash Flow Growth
+63.6%
Year-over-Year

SUPRIYA Income Statement — Revenue, EBITDA & Net Profit

Supriya Lifescience revenue ₹828 Cr, EBITDA ₹294 Cr, net profit ₹213 Cr, EPS ₹25.98 (2026) — net profit margin 25.7%. Also explore SUPRIYA share price data to track price trends across different timeframes.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 828 706 581 470 538 396 323 286 222 191 172 140
Expenses 534 436 397 332 316 218 213 213 191 166 150 121
EBITDA 294 271 184 138 222 178 110 73 31 25 22 20
Operating Profit Margin % 35.00% 37.00% 30.00% 28.00% 40.00% 44.00% 32.00% 23.00% 10.00% 9.00% 12.00% 12.00%
Depreciation 28 20 16 12 10 7 6 5 5 5 4 3
Interest 2 2 2 3 4 4 7 10 11 12 10 7
Profit Before Tax 275 249 166 124 207 167 96 57 15 8 8 10
Tax 61 61 47 34 55 44 23 18 6 2 2 2
Net Profit 213 188 119 90 152 124 73 39 9 6 6 8
Earnings Per Share (₹) 25.98 23.35 14.80 11.16 18.86 16.89 10.02 5.39 1.19 3.87 3.89 16.82

SUPRIYA Balance Sheet — Assets, Liabilities & Shareholders' Equity

SUPRIYA total assets ₹1,357 Cr, total equity ₹1,198 Cr, total liabilities ₹ Cr (2026) — ROE 17.8%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 1,357 1,112 921 820 735 446 336 253 245 241 231 176
Current Assets 532 437 398 465 498 266 196 133 120 115 129 103
Fixed Assets 725 453 310 262 190 100 99 85 91 89 76 61
Capital Work in Progress 36 148 149 68 43 79 40 35 34 36 25 11
Investments 160 63 64 25 0 0 0 0 0 0 0 0
Other Assets 0 448 399 466 502 267 197 133 120 117 131 104
LIABILITIES
Total Liabilities
Current Liabilities 38 33 29 25 19 31 32 24 45 51 39 23
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 1,198 997 815 700 616 269 149 94 55 46 42 37
Share Capital 16 16 16 16 16 15 15 15 15 15 15 5
Reserves & Surplus 1,182 981 799 683 600 254 134 79 40 31 26 33

SUPRIYA Cash Flow Statement — Operating, Investing & Financing

Supriya Lifescience operating cash flow ₹165 Cr, investing ₹-152 Cr, financing ₹-8 Cr, net cash flow ₹4 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 165 113 64 49 76 117 49 28 27 14 -6
Investing Activities -152 -174 -124 -60 -47 -25 5 -5 -27 -33 -23
Financing Activities -8 -22 -10 150 -15 -29 -50 -20 -2 21 30
Net Cash Flow 4 -83 -70 139 15 62 4 3 -2 2 1